Aneustat (OMN54) has aerobic glycolysis‐inhibitory activity and also immunomodulatory activity as indicated by a first‐generation PDX prostate cancer model

Aneustat (OMN54) is a multivalent, botanical anticancer candidate therapeutic. A recent Phase‐I clinical trial has indicated that it is well tolerated by patients and has immunomodulatory activity. In our study, using in vitro and in vivo prostate cancer models, we investigated Aneustat with regard...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Cancer
Main Authors: Qu, Sifeng, Xue, Hui, Dong, Xin, Lin, Dong, Wu, Rebecca, Nabavi, Noushin, Collins, Colin C., Gleave, Martin E., Gout, Peter W., Wang, Yuzhuo
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Cancer Therapy and Prevention
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6001442/
https://ncbi.nlm.nih.gov/pubmed/29441566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.31310
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki